STOCK TITAN
  1. Home
  2. Sec-filings
  3. AGEN
  4. [Form 4] AGENUS INC Insider Trading Activity

Agenus (AGEN) director Brian Corvese granted 210,000 stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Agenus Inc. director Brian Corvese received a grant of 210,000 stock options for Agenus Inc. common stock. The options were awarded on April 24, 2026 under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan at an exercise price of $3.90 per share.

The award vests on the one-year anniversary of the grant date and expires on April 24, 2036. After this grant, Corvese holds 210,000 stock options directly. This is a compensation-related award rather than an open-market share purchase or sale.

Positive

  • None.

Negative

  • None.
Insider Corvese Brian
Role null
Type Security Shares Price Value
Grant/Award Stock Option 210,000 $0.00 --
Holdings After Transaction: Stock Option — 210,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Stock option grant size 210,000 options Grant to director on April 24, 2026
Exercise price $3.90 per share Strike price of granted stock options
Options held after grant 210,000 options Total stock options following transaction
Vesting schedule 1-year cliff Vests on one-year anniversary of grant date
Option expiration date April 24, 2036 Final exercise date for the granted options
Stock Option financial
"security_title: "Stock Option" for derivative transaction"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
2019 Amended and Restated Equity Incentive Plan financial
"Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan"
vests financial
"vests on the one-year anniversary of the grant date"
expiration date financial
"expiration_date: 2036-04-24T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Corvese Brian
(Last)(First)(Middle)
C/O AGENUS INC.
3 FORBES ROAD
(Street)
LEXINGTON MASSACHUSETTS 02421
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
AGENUS INC [ AGEN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/24/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option$3.904/24/2026A210,000 (1)04/24/2036Common Stock210,000$0.00210,000D
Explanation of Responses:
1. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests on the one-year anniversary of the grant date.
/s/Austin Charette, as Attorney-in-Fact for Brian Corvese04/28/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Agenus (AGEN) director Brian Corvese report in this Form 4?

Brian Corvese reported receiving an award of 210,000 stock options for Agenus common stock. The grant is a compensation-related award, not a market purchase or sale, and reflects equity-based pay aligned with the company’s long-term incentive plan.

What are the key terms of Brian Corvese’s Agenus (AGEN) stock option grant?

The grant covers 210,000 stock options with a $3.90 per share exercise price. The options were awarded on April 24, 2026, vest after one year, and expire on April 24, 2036, providing long-dated equity exposure linked to Agenus’s share performance.

Is the Agenus (AGEN) Form 4 transaction a stock purchase or sale?

The Form 4 reports a grant of stock options, not an open-market purchase or sale. Code A indicates a grant or award acquisition, meaning Corvese received options as compensation rather than trading existing Agenus shares in the market.

How many Agenus (AGEN) options does Brian Corvese hold after this grant?

Following the reported transaction, Corvese holds 210,000 stock options directly. The filing shows this as his total option position after the grant, giving him the right, once vested, to buy Agenus common shares at $3.90 per share.

When do Brian Corvese’s Agenus (AGEN) stock options vest and expire?

The stock options vest on the one-year anniversary of the April 24, 2026 grant date. They carry an expiration date of April 24, 2036, giving Corvese a ten-year window after grant to exercise the options once they are vested.